Skip to main content
SpringerLink
Log in

UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Previous studies of irinotecan pharmacogenetics have shown that the UGT1A1*28 polymorphism has an effect on irinotecan (IRI)-induced toxicities in Caucasians. Yet compared with the UGT1A1*6 mutation, the UGT1A1*28 occurs at a much lower frequency in the Asians. Whether UGT1A1*6 and UGT1A1*28 are associated with IRI-induced neutropenia, diarrhea and IRI-based chemotherapy tumor response (TR) in Asians with lung cancer remains controversial. In this meta-analysis, we found a higher risk of neutropenia and diarrhea with IRI-based chemotherapy in Asians with lung cancer carrying the UGT1A1*6 polymorphism. However, UGT1A1*28 showed a weak correlation with diarrhea, but no significant correlation with neutropenia. Neither UGT1A1*6 nor UGT1A1*28 is associated with IRI-based chemotherapy TR. These data suggest that the UGT1A1*28 polymorphism may not be a suitable biomarker to predict IRI-induced toxicities and chemotherapy TR in Asians, while UGT1A*6 polymorphism is associated with a higher risk of IRI-induced neutropenia and diarrhea, but not IRI-based chemotherapy TR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics †. Ca A Cancer J Clin 61:69–90

  2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132

    Article  PubMed  Google Scholar 

  3. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380

    Article  CAS  PubMed  Google Scholar 

  4. Yang XQ, Li CY, Xu MF, Zhao H, Wang D (2015) Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis. BMC Cancer 15:949

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kazumasa N, Yutaka N, Masaaki K, Shunichi N, Takahiko S, Akira Y, Masahiro F, Kiyoshi M, Koshiro W, Tomohide T (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91

    Article  Google Scholar 

  6. Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrom S, Thaning L, Vilsvik J, Aasebo U, Sorenson S (2008) Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 26:4261–4267

    Article  CAS  PubMed  Google Scholar 

  7. Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245–259

    Article  CAS  PubMed  Google Scholar 

  8. Premawardhena A, Fisher CA, Liu YT, Verma IC, De Silva S, Arambepola M, Clegg JB, Weatherall DJ (2003) The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis 31:98–101

    Article  CAS  PubMed  Google Scholar 

  9. Kaniwa N, Kurose K, Jinno H, Tanakakagawa T, Saito Y, Saeki M, Sawada J, Tohkin M, Hasegawa R (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American. Drug Metab Dispos 33:458–465

    Article  CAS  PubMed  Google Scholar 

  10. Fukui T, Mitsufuji H, Kubota M, Inaoka H, Hirose M, Iwabuchi K, Masuda N, Kobayashi H (2011) Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent. Oncol Lett 2:923–928

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N (2007) Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17:497

    Article  CAS  Google Scholar 

  12. Schilsky RL (2010) Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 9:363–366

    Article  CAS  PubMed  Google Scholar 

  13. Fei HF, Long GC, Dan Y, Jin Z, Li GL, Run LG, Li LY, He L, An Guang Y, Hong LL (2014) Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemother Pharmacol 73:779–788

    Article  Google Scholar 

  14. Chen YJ, Hu F, Li CY, Fang JM, Chu L, Zhang X, Xu Q (2014) The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Biomarkers 19:56

    Article  CAS  PubMed  Google Scholar 

  15. Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, Liu BR, Xu GX, Dong XL, Qian XP (2014) UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemother Pharmacol 73:551

    Article  CAS  PubMed  Google Scholar 

  16. Janssens A, Cecile JW (2011) Strengthening the reporting of Genetic Risk Prediction Studies: the GRIPS statement. Eur J Clin Investig 3:1004–1009

  17. Jorgensen AL, Williamson PR (2008) Methodological quality of pharmacogenetic studies: issues of concern. Stat Med 27:6547–6569

    Article  PubMed  Google Scholar 

  18. Moher D, Liberati A, Tetzlaff J, Altman DG, Group The Prisma (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336–341

  19. Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28:123–137

    Article  PubMed  Google Scholar 

  20. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T (1998) UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9:845–847

    Article  CAS  PubMed  Google Scholar 

  21. Yamamoto N, Takahashi T, Kunikane H, Masuda N, Eguchi K, Shibuya M, Takeda Y, Isobe H, Ogura T, Yokoyama A, Watanabe K (2009) Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther 85:149–154

    Article  CAS  PubMed  Google Scholar 

  22. Lara Jr PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530–2535

    Article  Google Scholar 

  23. Harada T, Saito H, Karino F, Isaka T, Murakami S, Kondo T, Oshita F, Miyagi Y, Yamada K (2014) Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the initiation of irinotecan-based chemotherapy. Mol Clin Oncol 2:737–743

    PubMed  PubMed Central  Google Scholar 

  24. Ma L, Chen Y, Yang C, Jiang H, Zhu J, Cheng Y (2015) Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer. Zhonghua zhong liu za zhi [Chin J Oncol] 37:29–32

    CAS  Google Scholar 

  25. Yun F, Lulu M, Zhiyu H, Lei G, Haifeng Y, Tao L, Haiyan Y, Conghua X (2014) Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer. J Cancer Res Ther 10(Suppl):C195–C200

    PubMed  Google Scholar 

  26. Xiao XG, Xia S, Zou M, Mei Q, Zhou L, Wang SJ, Chen Y (2015) The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. OncoTargets and Therapy 8:3575–3583

    Article  PubMed  PubMed Central  Google Scholar 

  27. Nakamura Y, Soda H, Oka M, Kinoshita A, Fukuda M, Fukuda M, Takatani H, Nagashima S, Soejima Y, Kasai T, Nakatomi K, Masuda N, Tsukamoto K, Kohno S (2011) Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. J Thorac Oncol 6:121–127

    Article  PubMed  Google Scholar 

  28. Fukuda M, Suetsugu T, Shimada M, Kitazaki T, Hashiguchi K, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Sugio K, Semba H, Nakanishi Y, Ichinose Y (2016) Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: results of Lung Oncology Group in Kyusyu (LOGIK1004B. Thorac Cancer 7:467–472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Han JY, Lim HS, Park YH, Lee SY, Lee JS (2009) Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 63:115–120

    Article  PubMed  Google Scholar 

  30. Han JY, Lim HS, Eun SS, Yoo YK, Yong HP, Lee JE, Jang IJ, Dae HL, Jin SL (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237–2244

    Article  CAS  PubMed  Google Scholar 

  31. Shi Y, Hu Y, Hu X, Li X, Lin L, Han X (2015) Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: a multicenter randomized controlled clinical trial. Thorac Cancer 6:785–791

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Sugiyama T, Hirose T, Kusumoto S, Shirai T, Yamaoka T, Okuda K, Ohnishi T, Ohmori T, Adachi M (2010) The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Oncol Res 18:337–342

    Article  PubMed  Google Scholar 

  33. Huxing Sheng, Lin Lin, Miao Zhang Miao, Zhi Hao Xue, Ping Wang Zi (2014) Analysis of relationship between the UGT1A1 gene polymorphisms and toxicity as well as efficacy in patients with small cell lung cancer treated with irinotecan. Chin J Cancer Prev Treatm 21:858–861

    Google Scholar 

  34. Hu ZY, Yu Q, Pei Q, Guo C (2010) Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res 16:3832–3842

    Article  CAS  PubMed  Google Scholar 

  35. Yi HZ, Qi Y, Sheng ZY (2010) Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer 46:1856–1865

    Article  Google Scholar 

  36. Dias MM, Mckinnon RA, Sorich MJ (2012) Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics 13:889–899

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Xuewei Chen and Liping Liu contributed equally to this work.

Authors and Affiliations

  1. Department of Thoracic Surgery, Guangzhou Institute of Respiratory Disease and State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, No 151, Yanjiang Rd, Guangzhou, 510120, Guangdong, People’s Republic of China

    Xuewei Chen, Zhihua Guo, Wenhua Liang, Jiaxi He, Minzhang Guo, Yang Liu, Qihua He & Jianxing He

  2. The Translational Medicine Laboratory, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China

    Xuewei Chen, Liping Liu, Liyan Huang, Qiuhua Deng, Hailing Tang, Hui Pan, Minzhang Guo & Jianxing He

  3. Key Cite of National Clinical Research Center for Respiratory Disease, Guangzhou, People’s Republic of China

    Xuewei Chen, Liping Liu, Zhihua Guo, Wenhua Liang, Jiaxi He, Liyan Huang, Qiuhua Deng, Hailing Tang, Hui Pan, Minzhang Guo, Yang Liu, Qihua He & Jianxing He

Authors
  1. Xuewei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liping Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhihua Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenhua Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiaxi He
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liyan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qiuhua Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hailing Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hui Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Minzhang Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Qihua He
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jianxing He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianxing He.

Ethics declarations

Funding

This study was supported by the National Natural Science Foundation of China (Grant No. 81301998); the Pearl River Nova Program of Guangzhou (Grant No. 2014J2200011); the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (Grant No. 2014A030306013). We would like to acknowledge Lindsey Hamblin for correcting our English spelling and grammar.

Conflict of interest

No potential conflicts of interest were disclosed.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (TIFF 8775 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, X., Liu, L., Guo, Z. et al. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis. Cancer Chemother Pharmacol 79, 1109–1117 (2017). https://doi.org/10.1007/s00280-017-3306-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-017-3306-9

Keywords

Search

Navigation